Prosecution Insights
Last updated: April 18, 2026
Application No. 17/987,071

MOGROSIDES AND USE THEREOF

Final Rejection §DP
Filed
Nov 15, 2022
Examiner
HOWELL, THEODORE R
Art Unit
1628
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Purecircle Usa Inc.
OA Round
2 (Final)
67%
Grant Probability
Favorable
3-4
OA Rounds
2y 7m
To Grant
92%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allow Rate
671 granted / 1006 resolved
+6.7% vs TC avg
Strong +25% interview lift
Without
With
+25.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
51 currently pending
Career history
1057
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
34.2%
-5.8% vs TC avg
§102
20.5%
-19.5% vs TC avg
§112
16.9%
-23.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1006 resolved cases

Office Action

§DP
DETAILED ACTION The amendment submitted on February 12, 2026 has been entered. Claims 21-27 are pending in the application and are rejected for the reasons set forth below. No claim is allowed. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Withdrawn Objections and Rejections The objections to the specification and drawings are withdrawn in view of the amendments thereto. The objection to claim 21 is withdrawn because the “Fig.” numbers have been deleted. The rejection of claims 24-27 under 35 U.S.C. 112(b) as being indefinite is withdrawn in view of applicant’s corrective amendment. The rejection of claims 21-24 under 35 U.S.C. 101 because they are drawn to a natural product is withdrawn because the examiner finds applicant’s arguments to be persuasive. Briefly, the examiner agrees that the “consumable” referred to in the instant claims is defined in applicant’s own specification at being something other than what is found in nature. See applicant’s Remarks, submitted February 12, 2026, at pp. 1-4. Maintained Rejections Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP 717.02 for applications subject to examination under the first-inventor-to-file provisions of the AIA as explained in MPEP 2159. See MPEP 2146 et seq. for applications not subject to examination under the first-inventor-to-file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP 804(I)(B)(1). For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms that may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/terminaldisclaimer. Claims 21-27 remain rejected on the ground of nonstatutory double patenting as being unpatentable over Patent No. 11,547,128 B2. Although the claims at issue are not identical, they are not patentably distinct from each other. The ‘128 Patent (cited in the prior action), of which the present application is a continuation, claims “[a] composition comprising at least one isolated or purified mogroside compound having a chemical structure represented in any of formulae 1, 2, 4, 5, 7, 8, 9, 11, 12, 14 and 15 … and at least one flavor ingredient, wherein the concentration of at least one isolated or purified mogroside compound is below the threshold flavor recognition concentration of the compound.” See claim 1 of the ‘128 Patent. Dependent claims 4-5 of the ‘128 Patent are drawn to consumable products, such as beverages and food products. Claim 3 of the ‘128 Patent lists substantially the same sweeteners as those listed in instant claims 24-25. Response to Arguments Applicant has not responded to this basis for rejection, so it is maintained. See applicant’s Remarks, submitted February 12, 2026, at p. 5. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Theodore R. Howell whose telephone number is (571)270-5993. The examiner can normally be reached Monday - Thursday, 8:00 am - 7:00 pm (Eastern Time). Exam-iner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L. Clark can be reached at (571)272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https:// patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. THEODORE R. HOWELL Primary Examiner Art Unit 1628 /THEODORE R. HOWELL/ Primary Examiner, Art Unit 1628 April 1, 2026
Read full office action

Prosecution Timeline

Nov 15, 2022
Application Filed
Nov 12, 2025
Non-Final Rejection — §DP
Feb 12, 2026
Response Filed
Apr 01, 2026
Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595248
PRMT5 INHIBITORS
2y 5m to grant Granted Apr 07, 2026
Patent 12594282
USE OF SMALL MOLECULE COMPOUNDS IN THE TREATMENT OF DISEASES MEDIATED BY LUNG EPITHELIAL CELL INJURY AND/OR VASCULAR ENDOTHELIAL CELL INJURY
2y 5m to grant Granted Apr 07, 2026
Patent 12595250
SUBSTITUTED PYRIMIDINE COMPOUNDS AS MULTIFUNCTIONAL RADICAL QUENCHERS AND THEIR USES
2y 5m to grant Granted Apr 07, 2026
Patent 12577214
POLYMORPHS OF BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AND USES THEREOF
2y 5m to grant Granted Mar 17, 2026
Patent 12551455
COMPOSITIONS AND METHODS FOR KETO STACKING WITH BETA-HYDROXYBUTYRATE AND ACETOACETATE
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
67%
Grant Probability
92%
With Interview (+25.4%)
2y 7m
Median Time to Grant
Moderate
PTA Risk
Based on 1006 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month